Advertisement
Mayo Clinic Proceedings Home

In reply—Amikacin Liposome Inhalation Suspension as a Treatment Option for Refractory Nontuberculous Mycobacterial Lung Disease Caused by Mycobacterium avium Complex

      We thank Swenson and Del Parigi
      • Swenson C.
      • Del Parigi A.
      Amikacin liposome inhalation suspension as a treatment option for refractory nontuberculous mycobacterial lung disease caused by Mycobacterium avium complex.
      for their comments on our article.
      • Shulha J.A.
      • Escalante P.
      • Wilson J.W.
      Pharmacotherapy approaches in nontuberculous mycobacteria infections.
      The article originally submitted on September 6, 2018. This formulation of amikacin inhalation (Arikayce) received Food and Drug Administration approval on September 28, 2018. Although we agreed that liposomal amikacin is an important therapeutic option for refractory mycobacterium avium complex pulmonary disease, at the time of our original submission we had included timely information on pages 1574 to 1575. Unfortunately, we did not have the Food and Drug Administration–approved dosage of Arikayce at the time of submission nor did the reviewers request us to include this information in Table 2 upon editing.

      References

        • Swenson C.
        • Del Parigi A.
        Amikacin liposome inhalation suspension as a treatment option for refractory nontuberculous mycobacterial lung disease caused by Mycobacterium avium complex.
        Mayo Clin Proc. 2020; 95: 201-202
        • Shulha J.A.
        • Escalante P.
        • Wilson J.W.
        Pharmacotherapy approaches in nontuberculous mycobacteria infections.
        Mayo Clinic Proc. 2019; 94: 1567-1581

      Linked Article

      • Amikacin Liposome Inhalation Suspension as a Treatment Option for Refractory Nontuberculous Mycobacterial Lung Disease Caused by Mycobacterium avium Complex
        Mayo Clinic ProceedingsVol. 95Issue 1
        • Preview
          We read with much interest the review by Shulha et al.1 The article is a comprehensive and well-written overview of pharmacological treatment approaches of nontuberculous mycobacterial (NTM) diseases. Table 2 (titled “NTM Medication Dosing, Adverse Effects, and Recommended Monitoring”), however, did not include an approved treatment option for NTM lung disease caused by Mycobacterium avium complex (MAC), namely, amikacin liposome inhalation suspension (ALIS; Arikayce). Amikacin liposome inhalation suspension is the first Food and Drug Administration (FDA)–approved medication with a specific indication for refractory MAC lung disease (MAC-LD).
        • Full-Text
        • PDF
      • Pharmacotherapy Approaches in Nontuberculous Mycobacteria Infections
        Mayo Clinic ProceedingsVol. 94Issue 8
        • Preview
          Nontuberculous mycobacteria (NTM) comprise a heterogeneous group of organisms, with only a small subset known to cause disease in humans. Although NTM infection is not a reportable disease, both the increasing clinical recognition and recent advancements in laboratory diagnostic capabilities of NTM infections in immunocompromised and immunocompetent patients are rapidly evolving. We reviewed antimicrobial agents used to treat the most frequently encountered NTM infections and examined optimized drug dosing strategies, toxicity profiles, drug-drug interactions, and the role of therapeutic drug monitoring.
        • Full-Text
        • PDF